Cyclenium Pharma is a growing pharmaceutical R&D company exploiting its next generation CMRT™ macrocyclic drug discovery technology to identify novel small molecule therapeutics for difficult disease targets in areas of unsatisfied medical need. Cyclenium is creating value through progression of internal programs in oncology, infectious diseases and inflammation/pain. In addition, Cyclenium is providing its extensive experience and exploring its CMRT-based QUEST™ screening library in risk-sharing partnerships with leading academic and research driven non-profit organizations as well as collaborations with innovative pharmaceutical and biotechnology companies world-wide seeking to modulate unique and difficult disease targets in diverse therapeutic areas. As part of a recent expansion of our R&D efforts, Cyclenium is seeking creative and talented scientists with advanced degrees in Medicinal/Organic or Analytical Chemistry. Please see the careers page on our web site for additional details, http://www.cyclenium.com/open-positions/.
Looking for a particular Cyclenium Pharma Inc. employee's phone or email?
The Cyclenium Pharma Inc. annual revenue was $811000 in 2026.
Dwight MacDonald is the Co-Founder and Principal Scientist of Cyclenium Pharma Inc..
9 people are employed at Cyclenium Pharma Inc..
Cyclenium Pharma Inc. is based in Montreal, Quebec.
The NAICS codes for Cyclenium Pharma Inc. are [3254, 32, 32541, 325].
The SIC codes for Cyclenium Pharma Inc. are [283, 28].